Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-23T12:07:02.326Z Has data issue: false hasContentIssue false
  • English
  • Français

Switching cholinesterase inhibitors in older adults with dementia

Published online by Cambridge University Press:  03 November 2010

Fadi Massoud ,
Julie Eve Desmarais  and
Serge Gauthier
Fadi Massoud*
Affiliation:
Centre Hospitalier de l'Université de Montréal (CHUM), Hôpital Notre-Dame, Service de Gériatrie, Montreal, Quebec, Canada
Julie Eve Desmarais
Affiliation:
Department of Psychiatry, McGill University, Montreal, Quebec, Canada
Serge Gauthier
Affiliation:
Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Douglas Mental Health University Institute, Verdun, Montreal, Quebec, Canada
*
Correspondence should be addressed to: Dr Fadi Massoud, Centre Hospitalier de l'Université de Montréal (CHUM), Hôpital Notre-Dame, Service de Gériatrie, 1560 Sherbrooke Est, Montreal, Quebec, H2L 4M1, Canada. Phone: +1 (514) 890–8000; Fax: +1 (514) 412–7506. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: Cholinesterase inhibitors (ChEIs) represent the mainstay of symptomatic treatment in Alzheimer's disease. Three medications belonging to this class are presently widely available. These agents differ in their individual mechanisms of action and pharmacokinetic properties. Switching ChEIs can be a reasonable option in cases of intolerance or lack of clinical benefit.

Methods: A systematic literature search of switching ChEIs was conducted, and all studies specifically evaluating this issue were identified. Published consensus guidelines were also searched for recommendations on ChEI switching.

Results: Eight clinical studies are summarized and discussed. All of these studies are open-label or retrospective and they cannot be readily compared because of heterogeneity in design, number of patients, agents used, and endpoints. Switching in most of these studies was done for both “lack of benefit” or “loss of response” after up to 29 months of treatment. Nevertheless, the majority of studies did not include individuals switched for lack of response after several years of treatment. Lack of satisfactory response or intolerance with the initial agent was not predictive of similar results with the second agent.

Conclusions: In light of these findings, we propose the following practical approach to switching ChEIs: (1) in the case of intolerance, switching to a second agent should be done only after the complete resolution of side-effects following discontinuation of the initial agent; (2) in the case of lack of efficacy, switching can be done overnight, with a quicker titration scheme thereafter; (3) switching ChEIs is not recommended in individuals who show loss of benefit several years after initiation of treatment.

Keywords

Alzheimer's diseasetreatmentdonepezilgalantaminerivastigmine
Type
Review Article
Information
International Psychogeriatrics , Volume 23 , Issue 3 , April 2011 , pp. 372 - 378
Copyright
Copyright © International Psychogeriatric Association 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Auriacombe, S., Pere, J. J., Loria-Kanza, Y. and Vellas, B. (2002). Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical Research and Opinion, 18, 129–138.CrossRefGoogle ScholarPubMed
Bartorelli, L. et al. (2005). Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Current Medical Research and Opinion, 21, 1809–1818.CrossRefGoogle ScholarPubMed
Bullock, R. and Connolly, C. (2002). Switching cholinesterase inhibitor therapy in Alzheimer's disease: donepezil to rivastigmine, is it worth it? International Journal of Geriatric Psychiatry, 17, 288–289.CrossRefGoogle ScholarPubMed
Burns, A. et al. (2006). Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of Psychopharmacology, 20, 732–755.CrossRefGoogle ScholarPubMed
Dantoine, T., Auriacombe, S., Sarazin, M., Becker, H., Pere, J. J. and Bourdeix, I. (2006). Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. International Journal of Clinical Practice, 60, 110–118.CrossRefGoogle ScholarPubMed
Darreh-Shori, T. et al. (2002). Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology, 59, 563–572.CrossRefGoogle ScholarPubMed
Darvesh, S., Hopkins, D. A. and Geula, C. (2003). Neurobiology of butyrylcholinesterase. Nature Reviews Neurosciences, 4, 131–138.CrossRefGoogle ScholarPubMed
Davidsson, P., Blennow, K., Andreasen, N., Eriksson, B., Minthon, L. and Hesse, C. (2001). Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neuroscence Letters, 300, 157–160.CrossRefGoogle ScholarPubMed
Dybicz, S. B., Keohane, D. J., Erwin, W. G., McRae, T. and Shah, S. N. (2006). Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. American Journal of Geriatric Pharamacotherapy, 4, 154–160.CrossRefGoogle ScholarPubMed
Gardette, V. et al. (2010). Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs, 24, 431–442.CrossRefGoogle ScholarPubMed
Gauthier, S., Juby, A., Morelli, L., Rehel, B. and Schecter, R. (2006). A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Current Medical Research and Opinion, 22, 2251–2265.CrossRefGoogle ScholarPubMed
Herrmann, N. et al. (2007). A population-based study of cholinesterase inhibitor use for dementia. Journal of the American Geriatrics Society, 55, 1517–1523.CrossRefGoogle ScholarPubMed
Herrmann, N., Binder, C., Dalziel, W., Smyth, S. and Camacho, F. (2009). Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs and Aging, 26, 403–407.CrossRefGoogle ScholarPubMed
Hogan, D. B. et al. (2007). Management of mild to moderate Alzheimer's disease and dementia. Alzheimers and Dementia, 3, 355–384.CrossRefGoogle ScholarPubMed
Jann, M. W., Shirley, K. L. and Small, G. W. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clinical Pharmacokinetics, 41, 719–739.CrossRefGoogle ScholarPubMed
Massoud, F. and Gauthier, S. (2010). Update on the pharmacological treatment of Alzheimer's disease. Current Neuropharmacology, 8, 69–80.CrossRefGoogle ScholarPubMed
Mohs, R. C. et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481–488.CrossRefGoogle ScholarPubMed
Mucha, L., Shaohung, S., Cuffel, B., McRae, T., Mark, T. L. and Del, V. M. (2008). Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. Journal of Managed Care Pharmacy, 14, 451–461.CrossRefGoogle ScholarPubMed
Onor, M. L., Trevisiol, M. and Aguglia, E. (2007). Rivastigmine in the treatment of Alzheimer's disease: an update. Clinical Interventions in Aging, 2, 17–32.CrossRefGoogle ScholarPubMed
Perry, E. K., Perry, R. H., Blessed, G. and Tomlinson, B. E. (1978). Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathology and Applied Neurobiology, 4, 273–277.CrossRefGoogle ScholarPubMed
Robinson, D. M. and Plosker, G. L. (2006). Galantamine extended release in Alzheimer's disease: profile report. Drugs and Aging, 23, 839–842.CrossRefGoogle ScholarPubMed
Rogers, S. L., Doody, R. S., Pratt, R. D. and Ieni, J. R. (2000). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a U.S. multicentre open-label study. European Neuropsychopharmacology, 10, 195–203.CrossRefGoogle Scholar
Sadowsky, C. H. et al. (2005). Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Primary Care Companion to Journal of Clinical Psychiatry, 7, 43–48.Google ScholarPubMed
Sadowsky, C. H., Dengiz, A., Olin, J. T., Koumaras, B., Meng, X. and Brannan, S. (2009). Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 24, 267–275.CrossRefGoogle ScholarPubMed
Seltzer, B. (2007). Donepezil: an update. Expert Opinion Pharmacotherapy, 8, 1011–1023.CrossRefGoogle ScholarPubMed
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S. and Gergel, I. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291, 317–324.CrossRefGoogle ScholarPubMed
Wilkinson, D. G. and Howe, I. (2005). Switching from donepezil to galantamine: a double-blind study of two wash-out periods. International Journal of Geriatric Psychiatry, 20, 489–491.CrossRefGoogle ScholarPubMed